



#6
Linda
7/5/00

Please type a plus sign (+) inside this box → ☐

PTO/SB/81 (11-96)

Approved for use through 6/30/99. OMB 0651-0035

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**POWER OF ATTORNEY OR
AUTHORIZATION OF AGENT,
NOT ACCOMPANYING
APPLICATION**

Application Number	09/162,648
Filing Date	September 29, 1998
First Named Inventor	J.C. Hiserodt
Group Art Unit	1633
Examiner Name	Carrie Stroup, Ph.D.
Attorney Docket Number	SEQ-2

I hereby appoint:

☐ Practitioners at Customer Number

OR

☒ Practitioner(s) named below:

Place Customer
Number Bar Code
Label here

Name	Registration Number
Michael Schiff	40,253

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the Patent and Trademark Office connected therewith.

Please change the correspondence address for the above-identified application to:

☐ The above-mentioned Customer Number.

OR

<input checked="" type="checkbox"/> Firm or Individual Name	Michael O'Neill, President & C.E.O.				
Address	Meyer Pharmaceuticals.LLC				
Address	1761 Kaiser Avenue				
City	Irvine	State	CA	ZIP	92614
Country	U.S.A.				
Telephone	(949) 833-0711	Fax	(949) 833-0439		

I am the:


☐ Applicant.

☒ Assignee of record of the entire interest
Certificate under 37 CFR 3.73(b) was previously filed in this application

SIGNATURE of Applicant or Assignee of Record

Name	Michael O'Neill, President & C.E.O., Meyer Pharmaceuticals
Signature	<i>Michael O'Neill</i>
Date	5-18-00

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/96 (10-92)

CERTIFICATE UNDER 37 C.F.R. § 1.780

Docket No. 337452001100

In the application of: John C. Hiserodt
Serial No.: 09/162,648
Filed: September 29, 1998
For: CANCER IMMUNOTHERAPY USING ALLOSTIMULATED CELLS IN A MULTIPLE
SEQUENTIAL IMPLANTATION STRATEGY

Meyer Pharmaceuticals, LLC, a California corporation, certifies that it is the assignee of the entire right, title and interest in the patent application identified above by virtue of:

A chain of title from the inventor(s) of the patent application identified above, to the current assignee as shown below:


1. From : John C. Hiserodt
To: Meyer Pharmaceuticals, LLC
A true copy of each Assignment is attached hereto.

The undersigned has reviewed all the documents in the chain of title of the patent application identified above and, to the best of undersigned's knowledge and belief, title is in the assignee identified above.

The undersigned (whose title is supplied below) is empowered to sign this certificate on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Dated: 5-12-99


Name: Michael O'Neill
Title: President
Meyer Pharmaceuticals, LLC
1761 Kaiser Avenue
Irvine, California 92614

PTO/SB/96 (10-92)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

ASSIGNMENT SOLE

THIS ASSIGNMENT, by John C. Hiserodt (hereinafter referred to as the assignor), residing at 6722 Lawn Haven Drive, Huntington Beach, California 92648 witnesseth:

WHEREAS, said assignor has invented certain new and useful improvements in CANCER IMMUNOTHERAPY USING ALLOSTIMULATED CELLS IN A MULTIPLE SEQUENTIAL IMPLANTATION STRATEGY, set forth in an application for Letters Patent of the United States, having an oath or declaration executed on even date herewith; bearing Serial No. 09/162,648 and filed on September 29, 1998; and

WHEREAS, Meyer Pharmaceuticals, LLC a corporation duly organized under and pursuant to the laws of California and having its principal place of business at 1761 Kaiser Avenue, Irvine, California 92614 (hereinafter referred to as the assignee, Meyer Pharmaceuticals, LLC) is desirous of acquiring the entire right, title and interest in and to said inventions and said application for Letters Patent of the United States, and in and to any Letters Patent or Patents, United States or foreign, to be obtained therefor and thereon:

NOW, THEREFORE, in consideration of One Dollar (\$1.00) and other good and sufficient considerations, the receipt of which is hereby acknowledged, said assignor has sold, assigned, transferred and set over, and by these presents does sell, assign, transfer and set over, unto said assignee, Meyer Pharmaceuticals, LLC, its successors, legal representatives and assigns, the entire right, title and interest in and to the above-mentioned inventions, application for Letters Patent, and any and all Letters Patent or Patents in the United States of America and all foreign countries which may be granted therefor and thereon, and in and to any and all divisions, continuations and continuations-in-part of said application, or reissues or extensions of said Letters Patent or Patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by said assignee, Meyer Pharmaceuticals, LLC, for its own use and the use of its successors, legal representatives and assigns, to the full end of the term or terms for which Letters Patent or Patents may be granted, as fully and entirely as the same would have been held and enjoyed by the assignor, had this sale and assignment not been made.

AND for the same consideration, said assignor hereby covenants and agrees to and with said assignee, Meyer Pharmaceuticals, LLC its successors, legal representatives and assigns, that, at the time of execution and delivery of these presents, said assignor is the sole and lawful owner of the entire right, title and interest in and to said inventions and the application for Letters Patent above-mentioned, and that the same are unencumbered and that said assignor has good and full right and lawful authority to sell and convey the same in the manner herein set forth.

AND for the same consideration, said assignor hereby covenants and agrees to and with said assignee, Meyer Pharmaceuticals, LLC, its successors, legal representatives and assigns, that said assignor will, whenever counsel of said assignee, or the counsel of its successor, legal representatives and assigns, shall advise that any proceeding in connection with said inventions, or said application for Letters Patent, or any proceeding in connection with Letters Patent for said inventions in any country, including interference proceedings, is lawful and desirable, or that any division, continuation or continuation-in-part of any application for Letters Patent or any reissue or extension of any Letters Patent, to be obtained thereon, is lawful and desirable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the procurement, maintenance, enforcement and defense of Letters Patent for said inventions, without charge to said assignee, Meyer Pharmaceuticals, LLC, its successors, legal representatives and assigns, but at the cost and expense of said assignee, Meyer Pharmaceuticals, LLC, its successors, legal representatives and assigns.

AND said assignor hereby requests the Commissioner of Patents to issue said Letters Patent of the United States to said assignee, Meyer Pharmaceuticals, LLC as the assignee, Meyer Pharmaceuticals, LLC of said inventions and the Letters Patent to be issued thereon for the sole use said assignee, Meyer Pharmaceuticals, LLC, its successors, legal representatives and assigns.

5/12/99
Date

John C. Hiserodt
John C. Hiserodt